about
Macrocyclic inhibitors of HCV NS3 protease.Future therapy of hepatitis C.Discovery of Narlaprevir (SCH 900518): A Potent, Second Generation HCV NS3 Serine Protease Inhibitor.Synthesis of 9-[1-(substituted)-3-(phosphonomethoxy)propyl]adenine derivatives as possible antiviral agents.Synthesis and biological activity of 5',9-anhydro-3-purine-isonucleosides as potential anti-hepatitis C virus agents.Flow Injection Chemiluminescence Method for Determination of Ribavirin Based on Enhancement of Luminol-Persulfate Reaction
P2860
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Emerging therapies for hepatitis C virus infection.
@en
Emerging therapies for hepatitis C virus infection.
@nl
type
label
Emerging therapies for hepatitis C virus infection.
@en
Emerging therapies for hepatitis C virus infection.
@nl
prefLabel
Emerging therapies for hepatitis C virus infection.
@en
Emerging therapies for hepatitis C virus infection.
@nl
P2860
P356
P1476
Emerging therapies for hepatitis C virus infection.
@en
P2093
P2860
P356
10.1517/14728214.6.1.13
P407
P577
2001-04-01T00:00:00Z